V***6
发帖数: 333 | 1 龙头股的触角很长，伸到德国去了。
BioNTech and Pfizer announce regulatory approval from German authority Paul-
Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine
candidates
MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE
(Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (PFE), have
announced today that the German regulatory authority, the Paul-Ehrlich-
Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162
vaccine program to prevent COVID-19 infection.
BioNTech and Pfizer are jointly developing BNT162. The trial is the first
clinical trial of a COVID-19 vaccine candidate to start in Germany, and is
part of a global development program. Pfizer and BioNTech will also conduct
trials for BNT162 in the United States upon regulatory approval, which is
expected shortly. | p**x
发帖数: 6614 | 2 梅西，PFE烂到家了
Paul-
SE
have
【在 V***6 的大作中提到】
: 龙头股的触角很长，伸到德国去了。
: BioNTech and Pfizer announce regulatory approval from German authority Paul-
: Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine
: candidates
: MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE
: (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (PFE), have
: announced today that the German regulatory authority, the Paul-Ehrlich-
: Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162
: vaccine program to prevent COVID-19 infection.
: BioNTech and Pfizer are jointly developing BNT162. The trial is the first
|
|
